Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial

E. Anter, M. Mansour, DG. Nair, D. Sharma, TL. Taigen, P. Neuzil, EL. Kiehl, J. Kautzner, J. Osorio, S. Mountantonakis, A. Natale, JD. Hummel, AK. Amin, UR. Siddiqui, D. Harlev, P. Hultz, S. Liu, B. Onal, KG. Tarakji, VY. Reddy, SPHERE PER-AF...

. 2024 ; 30 (8) : 2303-2310. [pub] 20240517

Language English Country United States

Document type Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc24019577
E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 38760584
DOI 10.1038/s41591-024-03022-6
Knihovny.cz E-resources

Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to challenges in achieving durable lesions. Although focal point-by-point ablation allows for the creation of any required lesion set, this strategy necessitates the generation of contiguous lesions without gaps. A large-tip catheter, capable of creating wide-footprint ablation lesions, may increase ablation effectiveness and efficiency. In a randomized, single-blind, non-inferiority trial, 420 patients with persistent AF underwent ablation using a large-tip catheter with dual pulsed field and radiofrequency energies versus ablation using a conventional radiofrequency ablation system. The primary composite effectiveness endpoint was evaluated through 1 year and included freedom from acute procedural failure and repeat ablation at any time, plus arrhythmia recurrence, drug initiation or escalation or cardioversion after a 3-month blanking period. The primary safety endpoint was freedom from a composite of serious procedure-related or device-related adverse events. The primary effectiveness endpoint was observed for 73.8% and 65.8% of patients in the investigational and control arms, respectively (P < 0.0001 for non-inferiority). Major procedural or device-related complications occurred in three patients in the investigational arm and in two patients in the control arm (P < 0.0001 for non-inferiority). In a secondary analysis, procedural times were shorter in the investigational arm as compared to the control arm (P < 0.0001). These results demonstrate non-inferior safety and effectiveness of the dual-energy catheter for the treatment of persistent AF. Future large-scale studies are needed to gather real-world evidence on the impact of the focal dual-energy lattice catheter on the broader population of patients with AF. ClinicalTrials.gov identifier: NCT05120193 .

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019577
003      
CZ-PrNML
005      
20241024110638.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41591-024-03022-6 $2 doi
035    __
$a (PubMed)38760584
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Anter, Elad $u Shamir Medical Center, Be'er Ya'Akov, Israel. eladan@shamir.gov.il
245    10
$a Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial / $c E. Anter, M. Mansour, DG. Nair, D. Sharma, TL. Taigen, P. Neuzil, EL. Kiehl, J. Kautzner, J. Osorio, S. Mountantonakis, A. Natale, JD. Hummel, AK. Amin, UR. Siddiqui, D. Harlev, P. Hultz, S. Liu, B. Onal, KG. Tarakji, VY. Reddy, SPHERE PER-AF Investigators
520    9_
$a Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to challenges in achieving durable lesions. Although focal point-by-point ablation allows for the creation of any required lesion set, this strategy necessitates the generation of contiguous lesions without gaps. A large-tip catheter, capable of creating wide-footprint ablation lesions, may increase ablation effectiveness and efficiency. In a randomized, single-blind, non-inferiority trial, 420 patients with persistent AF underwent ablation using a large-tip catheter with dual pulsed field and radiofrequency energies versus ablation using a conventional radiofrequency ablation system. The primary composite effectiveness endpoint was evaluated through 1 year and included freedom from acute procedural failure and repeat ablation at any time, plus arrhythmia recurrence, drug initiation or escalation or cardioversion after a 3-month blanking period. The primary safety endpoint was freedom from a composite of serious procedure-related or device-related adverse events. The primary effectiveness endpoint was observed for 73.8% and 65.8% of patients in the investigational and control arms, respectively (P < 0.0001 for non-inferiority). Major procedural or device-related complications occurred in three patients in the investigational arm and in two patients in the control arm (P < 0.0001 for non-inferiority). In a secondary analysis, procedural times were shorter in the investigational arm as compared to the control arm (P < 0.0001). These results demonstrate non-inferior safety and effectiveness of the dual-energy catheter for the treatment of persistent AF. Future large-scale studies are needed to gather real-world evidence on the impact of the focal dual-energy lattice catheter on the broader population of patients with AF. ClinicalTrials.gov identifier: NCT05120193 .
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x chirurgie $x terapie $7 D001281
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a katetrizační ablace $x metody $7 D017115
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a jednoduchá slepá metoda $7 D016037
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Mansour, Moussa $u Massachusetts General Hospital, Boston, MA, USA
700    1_
$a Nair, Devi G $u St. Bernards Medical Center & Arrhythmia Research Group, Jonesboro, AR, USA
700    1_
$a Sharma, Dinesh $u NCH Rooney Heart Institute, Naples, FL, USA
700    1_
$a Taigen, Tyler L $u Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000212588118
700    1_
$a Neuzil, Petr $u Na Homolce Hospital, Prague, Czechia
700    1_
$a Kiehl, Erich L $u Sentara, Norfolk, VA, USA
700    1_
$a Kautzner, Josef $u IKEM Prague, Prague, Czechia
700    1_
$a Osorio, Jose $u HCA Florida Miami, Miami, FL, USA
700    1_
$a Mountantonakis, Stavros $u Northwell, New Hyde Park, NY, USA
700    1_
$a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, Austin, TX, USA $u Department of Biomedicine and Prevention, Division of Cardiology, University of Tor Vergata, Rome, Italy
700    1_
$a Hummel, John D $u Division of Cardiology, Ohio State University, Columbus, OH, USA
700    1_
$a Amin, Anish K $u Riverside Methodist Hospital, Upper Arlington, OH, USA
700    1_
$a Siddiqui, Usman R $u Florida Cardiology, Orlando, FL, USA
700    1_
$a Harlev, Doron $u Medtronic, Mounds View, MN, USA
700    1_
$a Hultz, Paul $u Medtronic, Mounds View, MN, USA
700    1_
$a Liu, Shufeng $u Medtronic, Mounds View, MN, USA
700    1_
$a Onal, Birce $u Medtronic, Mounds View, MN, USA
700    1_
$a Tarakji, Khaldoun G $u Medtronic, Mounds View, MN, USA $1 https://orcid.org/0000000236622886
700    1_
$a Reddy, Vivek Y $u Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, NY, USA
710    2_
$a SPHERE PER-AF Investigators
773    0_
$w MED00003459 $t Nature medicine $x 1546-170X $g Roč. 30, č. 8 (2024), s. 2303-2310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38760584 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110632 $b ABA008
999    __
$a ok $b bmc $g 2202045 $s 1231550
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 8 $d 2303-2310 $e 20240517 $i 1546-170X $m Nature medicine $n Nat Med $x MED00003459
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options